Iranian Journal of Medical Physics (Jan 2022)

Dosimetric Comparison between Dynamic Wave Arc and Co-Planar Volumetric Modulated Radiotherapy for Locally Advanced Pancreatic Cancer

  • Alshaymaa Abdelghaffar,
  • Noriko Kishi,
  • Ryo Ashida,
  • Yukinori Matsuo,
  • Hideaki Hirashima,
  • Nobutaka Mukumoto,
  • Michio Yoshimura,
  • Mitsuhiro Nakamura,
  • Ahmed El Sayed Mohamed,
  • Elsayed Mostafa,
  • Mohamed Soliman Gaber,
  • Takashi Mizowaki

DOI
https://doi.org/10.22038/ijmp.2021.55707.1923
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 8

Abstract

Read online

Introduction: Dose reduction to the duodenum is important to decrease gastrointestinal toxicities in patients with locally advanced pancreatic cancer (LAPC) treated with definitive chemoradiotherapy. We aimed to compare dynamic wave arc (DWA), a volumetric-modulated beam delivery technique with simultaneous gantry/ring rotations passing the waved trajectories, with coplanar VMAT (co-VMAT) with respect to dose distributions in LAPC cases. Material and Methods: DWA and co-VMAT plans were created for 13 patients with LAPC. The prescribed dose was 45.6 or 48 Gy in 15 fractions. The dose volume indices (DVIs) for target volumes and organs at risk were compared between the corresponding plans. Gamma passing rate, monitor unit (MU), and beam-on time were also compared. Results: DWA significantly reduced the duodenal V39Gy, V42Gy, and V45Gy by 1.1, 0.8, and 0.2 cm3, and increased the liver mean dose and D2cm3 of the spinal cord planning volume by 1.0 and 1.5 Gy, respectively. Meanwhile, there was no significant difference in the target volumes except for D2% of PTV (111.5% in DWA vs. 110.5% in co-VMAT). Further, the gamma passing rate was similar in both plans. MU and beam-on time increased in DWA by 31 MUs and 15 seconds, respectively. Conclusion: DWA generated significantly lower duodenal doses in LAPC cases, albeit with slight increasing liver and spinal cord doses and increasing MU and the beam delivery time. Further evaluation is needed to know how the dose differences would affect the clinical outcomes in chemoradiotherapy for LAPC.

Keywords